Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REVCO TESTING PROGRAM FOR DRUGS OBTAINED FROM SECONDARY SOURCES INVOLVES RANDOM SAMPLING OF ALL PRODUCTS NOT OBTAINED FROM MFRS. OR WHSLRS.

Executive Summary

Revco has initiated a testing program to insure that all Rxs obtained from sources other than the original mfr. or an authorized distributor meet USP standards, the chain announced in a Sept. 26 release. "Effective immediately," Revco Chairman Sidney Dworkin announced, we "will implement a testing program for any drug product that is offered to us by a secondary supplier." Dworkin said that "the objective of this program is to certify that all our products are pure and safe, according to the United States Pharmacopia (USP) standards." Revco said that testing of the secondary supplied drugs will be conducted by Scientific Associates, an independent research and testing laboratory in St. Louis. The firm explained that products purchased from secondary suppliers would be kept separate from other products in their warehouses. Revco would then randomly pick a sample from each lot of those drug purchases and send it to Scientific Associates for analysis. Dworkin said that "if the testing of any lot reveals a product that fails to meet USP standards, the entire shipment will be rejected -- - no exceptions -- - and we will notify FDA." Safety of drugs obtained from secondary suppliers has been the focus of recent hill attention. At a July 10 hearing on drug diversion and counterfeiting, the House Commerce/Oversight Subcmte. released a report which included discussion of Revco's use of secondary sources for Rx products. Citing past instances where the chain purchased diverted Rx drugs, the report states that "Revco appears to have continued its practice of buying from diverters." According to the subcmte. report, a former Revco employee testified that "it made no difference to Revco where the initial diverters purchased the merchandise, as long as they were licensed." The report notes that the problem with that criteria "is that possessing a state license -- - which is quite easy to obtain -- - is no guarantee of quality." In announcing its new testing program, the chain noted that the practice of a retailer purchasing drugs from sources other than authorized distributors or the original mfr. is legal and provides opportunities to purchase products at favorable prices. The chain said it recognized the danger is with those "diverted drug products which have been contaminated, improperly stored, tampered with or adulterated, exceeded their expiration dates, or are outright counterfeits." Dworkin commented that "although, to our knowledge, Revco never has purchased a counterfeit drug, we feel strongly that active, aggressive steps must be taken to prevent this from occurring and thus protect the safety of our customers." He added that "it also is our hope that through the exposure of contaminated diverted products that we will contribute to eliminating these products from entering the market in the first place."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel